Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
  1. Home
  3. Research Domains

Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease.

Anna S Lok1, Leonard B Seeff, Timothy R Morgan

  • 1Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, Michigan 48109, USA. aslok@umich.edu

Gastroenterology
|October 14, 2008

Related Experiment Videos

View abstract on PubMed

Summary

Related Concept Videos

  • Biomedical And Clinical Sciences
  • Oncology And Carcinogenesis
  • Predictive And Prognostic Markers
  • Incidence Of Hepatocellular Carcinoma And Associated Risk Factors In Hepatitis C-related Advanced Liver Disease.
    • This summary is machine-generated.

    Maintenance peginterferon did not lower liver cancer rates in the HALT-C study. Older age, black race, and smoking were identified as key risk factors for hepatocellular carcinoma (HCC) in hepatitis C patients.

    Area of Science:

    • Hepatology
    • Oncology
    • Viral Hepatitis Research

    Background:

    • Hepatocellular carcinoma (HCC) incidence is rising in the US, with limited large-scale prospective data.
    • The Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) cohort provides a valuable dataset for studying HCC.
    • Understanding HCC incidence and risk factors in chronic hepatitis C is crucial for patient management.

    Purpose of the Study:

    • To evaluate HCC incidence within the HALT-C cohort.
    • To identify risk factors associated with HCC development in patients with chronic hepatitis C.
    • To assess the impact of maintenance peginterferon therapy on HCC incidence.

    Main Methods:

    • Prospective analysis of 1,005 patients with bridging fibrosis or cirrhosis from the HALT-C cohort.
    • Randomization to maintenance peginterferon or no treatment for 3.5 years.
    • Kaplan-Meier analysis for HCC incidence and Cox regression for risk factor identification.

    Main Results:

    • During a median follow-up of 4.6 years, 4.8% of patients developed HCC.
    • Cumulative 5-year HCC incidence was similar between peginterferon and control groups (5.4% vs. 5.0%).
    • HCC incidence was higher in patients with cirrhosis compared to bridging fibrosis (7.0% vs. 4.1%).
    • A multivariate model identified older age, black race, lower platelet count, higher alkaline phosphatase, esophageal varices, and smoking as HCC risk factors.

    Conclusions:

    • Maintenance peginterferon therapy did not significantly reduce HCC incidence in this cohort.
    • Baseline clinical and laboratory features effectively predict HCC risk.
    • Further research is needed to confirm HCC occurrence in patients with chronic hepatitis C and bridging fibrosis.

    Related Experiment Videos